NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.32 -0.09 (-0.11%) GOLD FUTURES
2,403.10 +20.10 (+0.84%) DOW
37,794.60 +59.49 (+0.16%) Bitcoin GBP
50,286.65 -1,148.41 (-2.23%)
Koninklijke Philips N.V. (PHG)
| Previous close | 20.41 |
| Open | 20.43 |
| Bid | 20.38 x 2200 |
| Ask | 20.40 x 1300 |
| Day's range | 20.25 - 20.44 |
| 52-week range | 17.75 - 24.27 |
| Volume | |
| Avg. volume | 1,025,362 |
| Market cap | 18.53B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 12 May 2022 |
| 1y target est | 20.52 |
ZacksPhilips (PHG) Agrees to a Consent Decree With DOJ and FDA
Philips (PHG) announces a consent decree with the U.S. government and FDA over Respironics' business recalls.
- Reuters
Philips shares rise on final US deal on sleep apnea machines
Philips said it had reached what is known as a consent decree that spells out the improvements it needs to make at its Respironics plants in the United States. In January, Philips said the costs of the consent decree led to a provision of 363 million euros in the fourth quarter of 2023, and were expected to be about 1% of total revenue in 2024. The agreement followed the recall of millions of breathing devices and ventilators used to treat sleep apnea in 2021, because of concerns that foam used to reduce noise from the devices could degrade and become toxic, carrying potential cancer risks.
GlobeNewswirePhilips Respironics reaches agreement with US government on a consent decree creating a clear path forward
April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA and Philips Respironics have now reached final agreement on the consent decree with the DOJ and FDA. As previously stated: The consent decree primarily focuses on Philips Respironics’ business operations in the US.It provides clarity and a roadmap to demonstrate compliance with regulatory requirements and to restore
